Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab

Emicizumab (Hemlibra™) is approved for prophylaxis of hemophilia A (HA) patients. The HAVEN studies addressed bleeding reduction in emicizumab-treated patients, but real-world data on bleeding patterns during emicizumab therapy are lacking. We aimed to compare the occurrence of breakthrough bleeding...

Descripción completa

Detalles Bibliográficos
Autores principales: Levy-Mendelovich, Sarina, Brutman-Barazani, Tami, Budnik, Ivan, Avishai, Einat, Barg, Assaf A., Levy, Tamara, Misgav, Mudi, Livnat, Tami, Kenet, Gili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509656/
https://www.ncbi.nlm.nih.gov/pubmed/34640320
http://dx.doi.org/10.3390/jcm10194303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509656/
https://www.ncbi.nlm.nih.gov/pubmed/34640320
http://dx.doi.org/10.3390/jcm10194303

Ejemplares similares